ARTICLE TO READ ON WORLD STROKE DAY, 2018!

Neuropharmacological Actions of Metformin in Stroke

 

Author(s): Jia Jia, Jian Cheng, Jingshu Ni, Xuechu Zhen.

 

 

 

Graphical Abstract:

 

 

 

Abstract:

Increasing epidemiologic evidence suggests that metformin, a well-established AMPK activator and the most favorable first-line anti-diabetic drug, reduces stroke incidence and severity. However, the mechanism for this remains unclear. Moreover, previous experimental studies have reported controversial results about the effects of metformin on stroke outcomes during the acute phase. However, recent studies have consistently suggested that AMPK-mediated microglia/macrophage polarization and angioneurogenesis may play essential roles in metformin-promoted, long-term functional recovery following stroke. The present review summarizes the neuropharmacological actions of metformin in experimental stroke with an emphasis on the recent findings that the cell-specific effects and duration of AMPK activation are critical to the effects of metformin on stroke outcomes.

 

For more details, please visit: http://www.eurekaselect.com/128222

PODCAST: The Role of Carbonic Anhydrase in Hepatic Glucose Production

Author(s):  Ibrahim S. Ismail*

For article details, visit: http://www.eurekaselect.com/148340

Subscribe our YouTube channelhttp://bit.ly/1lr0czy

Open Access Article – “Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect”

Journal: Endocrine, Metabolic & Immune Disorders – Drug Targets

Author(s): Yoshifumi Saisho

emiddt

Abstract: Metformin is an oral hypoglycemic agent which is most widely used as first-line therapy for type 2 diabetes. Metformin improves hyperglycemia by suppressing hepatic glucose production and increasing glucose uptake in muscle. Metformin also has been shown to reduce cardiovascular events in randomized controlled trials; however, the underlying mechanism remains to be established. Recent preclinical and clinical studies have suggested that metformin not only improves chronic inflammation through the improvement of metabolic parameters such as hyperglycemia, insulin resistance and atherogenic dyslipidemia, but also has a direct anti-inflammatory action. Studies have suggested that metformin suppresses inflammatory response by inhibition of nuclear factor κB (NFκB) via AMP-activated protein kinase (AMPK)-dependent and independent pathways. This review summarizes the basic and clinical evidence of the anti-inflammatory action of metformin and discusses its clinical implication.

Read more here: http://benthamscience.com/journals/endocrine-metabolic-and-immune-disorders-drug-targets/volume/15/issue/3/page/196/

%d bloggers like this: